Is cabozantinib included in the medical insurance catalog? Analysis of the latest reimbursement policy

Cabozantinib (Cabozantinib) has not yet been officially launched in China, and therefore has not been included in my country's medical insurance reimbursement catalog. This means that if domestic patients need to use the drug, they are temporarily unable to obtain reimbursement support through the medical insurance system, and it is also difficult to purchase it directly in domestic hospitals. Patients usually need to use formal overseas channels to obtain cabozantinib for treatment.

In overseas markets, the original drug versions of cabozantinib mainly include the European version, the Hong Kong version, the Japanese version and the Turkish version, etc., with a wide price range, with the latest selling price ranging from more than 20,000 yuan to more than 50,000 yuan. Due to the high price of original drugs, some patients may face greater financial pressure, limiting their widespread use.

In order to meet the medication needs of different patients, pharmaceutical companies in countries such as Laos and Bangladesh have launched officially marketed generic cabozantinib drugs. The ingredients of these generic drugs are basically the same as those of the original drugs, and they come in various specifications, including 20mg 90 tablets, 60mg 30 tablets, 80mg*30 tablets, etc. The prices are more affordable, usually ranging from more than 500 yuan to one or two thousand yuan. The emergence of generic drugs has provided patients with more affordable options.

Overall, although cabozantinib has not yet been included in medical insurance in China, patients can still obtain their treatment needs by purchasing generic drugs through formal overseas channels. It is recommended that patients rationally choose purchasing channels and specifications based on their own conditions and doctor's recommendations to ensure the safety and efficacy of medication. At the same time, pay attention to the future domestic approval and medical insurance developments of Cabozantinib in order to enjoy the policy dividends in a timely manner.

Reference materials:https://www.drugs.com